Biological Therapy for Inflammatory Bowel Disease in Children.
10.5223/pghn.2012.15.1.13
- Author:
So Young NA
1
;
Jung Ok SHIM
Author Information
1. Department of Pediatrics, Dongguk University College of Medicine, Goyang, Korea.
- Publication Type:Review
- Keywords:
Inflammatory bowel disease;
Infliximab;
Children
- MeSH:
Antibodies, Monoclonal;
Biological Agents;
Biological Therapy;
Child;
Crohn Disease;
Humans;
Immunoglobulin G;
Immunologic Factors;
Inflammatory Bowel Diseases;
Necrosis;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2012;15(1):13-18
- CountryRepublic of Korea
- Language:English
-
Abstract:
The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.
